|
Published by: Decision Resources
Published: Nov. 8, 2007 - 46 Pages The price of this report has been reduced due to its age. The original price was $3,800 for PDF.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- 25 Years of New Technologies—The Pendulum Is Swinging
- The Hunt Continues for the Next Best Antibody Technologies
- Technology Platforms Produce Designer Antibodies
- Antibody Technology Platform Deals
- Mergers & Acquisitions Still Blazing a Trail
- Personalized Medicine
- Enabling Biomarkers and Pharmacogenomics
- Recent Trends in Personalized Medicine
- Observed Trends
- Targeted RNA Therapy
- MicroRNAs
- The RNA Interference Mega-Deal Bandwagon
- Where Are the Opportunities Now?
- Venture Investing and Early-Stage Financings
- The Holy Grail of RNA Interference Is Effective Delivery
- Protein Optimization
- Immunogenicity Issues
- Antitope Immunogenicity Testing
- AlgoNomics Immunotuning and Deimmunization Technology
- Xencor Immunofi ltering Technology
- Decreasing Sensitivity to Proteolytic Degradation
- Pegylation
- Enzon and Nektar Therapeutics
- Prolong Pharmaceuticals
- Neose GlycoPEGylation
- Roche and Amgen
- Fusion Proteins
- Glycoengineering to Produce Designer Proteins and Antibodies
- Biolex Therapeutics Plant-Produced Therapeutic Protein Platform
- BioWa’s CDC- and ADCC-Enhanced Antibody Technology Platform
- GlycArt’s Glycoengineering and Enhanced Apoptosis Induction Technology Platform
- GlycoFi’s Yeast Glycoengineering and Optimization Technology Platform
- Glycotope
- Xoma’s Microbial Secretion and Antibody Production Technology Platform
- Stem Cell Therapy Market to Grow Rapidly
- Technology Opportunity Priorities
- Antibody Platforms
- Biomarker-Driven Targeted Therapies
- Personalized Medicine
- Protein Optimization and Glycoengineering
- RNA Interference
- Stem Cell Therapy
- Expert Commentary
- Expert Commentary: Biomarker-Driven Personalized Medicine is the Way Forward in Cancer Therapy
- Expert Commentary: An Analysis of Industry Trends in Personalized Medicine
- Expert Commentary: The Potential of miRNA Modulators as Targeted Oncology Therapies
- Tables
- 1. Hunting Deals for Therapeutic Antibody Technology Platforms, 2007
- 2. Select Rosetta Genomics microRNA Deals, 2006-2007
- 3. Select Alnylam Pharmaceuticals RNA Interference Deals, 2007
- 4. Select RNA Interference Deals, 2006-2007
- 5. Select Delivery Deals for Therapeutic RNA Interference, 2006-2007
- 6. Select Protein Optimization Deals, 2007
- 7. Comparison of Different Types of Stem Cells
- 8. Select Companies and Later-Stage Stem Cell Therapy Products, 2007
- 9. Stem Cell Therapy Deals, 2007
- Figures
- 1. Projected Growth in Biologics Sales, 2001-2010
- 2. MAbs: From Mouse to Human
- 3. A Blazing Mergers and Acquisition Trail for Antibody Companies, 2005-2007
- 4. Diaceutics Google Index (DGi) for Personalized Medicine, June 2005-June 2007
- 5. Targeted Therapy Through RNA Interference
- 6. Engineering Designer MAbs
- A-B. Tyrosine Kinases and Their Targeted Therapies
- C. Diaceutics Google Index (DGi) for Personalized Medicine Topics
- Experts Featured
- Fabricio F. Costa, Ph.D., post-doctoral fellow,
- Cancer Biology and Epigenomics Program, Children’s Memorial Research Center, Northwestern University’s Feinberg School of Medicine
- Mollie Roth, J.D., corporate counsel, vice president of business development at Diaceutics
- Chris Schutz, senior analyst, Millennium Research Group, a Decision Resources, Inc., company
- Jeffrey Settleman, Ph.D., professor of medicine at Harvard Medical School and director, Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center
- Thomas Wurdinger, Ph.D., post-doctoral fellow, Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital, and Program in Neuroscience,
- Harvard Medical School
AbstractTechnology revolutions, convergence, and new paradigms of drug discovery and development─these are
exciting times for the pharmaceutical industry. Technological innovation is fl ourishing and intense competition
exists among companies that hope to license or acquire the newest and best technology platforms. Some
markets are already hot, hot, hot, while others will require resources that few companies have to commit. But,
there is gold in new technologies, and companies do not want to risk being shut out in the cold without access to
at least some enabling technology. What will it take to out-compete the competition?
Get the Answers You Need to Shape Your Strategy
- Numerous new technologies are gaining the attention of, and being swept up by, Big Pharma and other •
partners. Which of these technologies is the most promising? Which technologies are generating the most
interest from investors? Which technology is being largely ignored, in spite of its promise?
- Biologics are not the only cutting edge innovation. Recent discoveries, including the sequencing of the •
human genome, have led to biomarkers, RNA interference, and a host of new targeted therapies. Because
no company can afford to invest in all of these new technologies, how can companies chose which
technologies to use or develop? Which technologies will drive the development of next-generation
products and which ones do companies ignore at their own risk?
- Increased competition has forced Big Pharma to invest in technology opportunities earlier than ever before. • Will
the reduced cost of unproven technology justify the increased risk? How are companies acquiring new
technologies and managing risk? What technology platforms and companies are they buying and why?
Scope
- Technology opportunities: • antibody platforms, biomarkers and pharmacogenomics, protein optimization,
glycoengineering, targeted RNA therapy, stem cell therapy.
- Dealmaking, mergers, and acquisitions: • snapshot of some of the many deals being struck by small
developers and biotechs and the larger partners who are funding them.
- Biologics: • recombinant protein and monoclonal antibody products and markets.
- RNA therapeutics: • RNA interference, microRNAs, effective delivery, multicomponent silencing cocktails,
tumor suppressors, antisense inhibitors
- Protein optimization: • glycoengineering, designer proteins, novel production systems, pegylation,
and deimmunization.
- Targeted therapies: • cancer therapies, tyrosine kinases, oncogene addiction, biomarkers, histologybased
pathology, molecular pathology, challenges, and opportunities.
- Personalized medicine: • convergence, disruptive technology, DNA-based diagnostics, Diaceutics
- Stem cells • : comparisons of different stem cell types, late-stage therapies, markets, and companies.
- Experts • : Commentary from fi ve experts working on targeted cancer therapies, personalized
medicine, RNA interference.
- Outlook: • a scorecard for six innovative technologies.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
